Inhibition of p38 MAPK sensitizes tumour cells to cisplatin‐induced apoptosis mediated by reactive oxygen species and JNK
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The p38 MAPK pathway is an important regulator of many cellular responses. It is well established that p38 MAPK signalling negatively regulates epithelial cell transformation, but enhanced p38 MAPK activity has been also correlated with bad clinical prognosis in some tumour types. Here, we provide genetic and pharmacological evidence showing that p38 MAPK inhibition cooperates with the chemotherapeutic agent cisplatin to kill tumour cells. We show that p38 MAPK inhibition results in ROS upregulation, which in turn activates the JNK pathway via inactivation of phosphatases, sensitizing human tumour cells to cisplatin‐induced apoptosis. Using a mouse model for breast cancer, we confirm that inhibition of p38 MAPK cooperates with cisplatin treatment to reduce tumour size and malignancy in vivo . Taken together, our results illustrate a new function of p38 MAPK that helps tumour cells to survive chemotherapeutic drug treatments, and reveal that the combination of p38 MAPK inhibitors with cisplatin can be potentially exploited for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 1×
“However, the pro ‐ tumourigenic effect of the accumulation of intracellular ROS can turn out to be a double ‐ edged sword, since high ROS levels may lower the apoptotic threshold for cytotoxicity (Trachootham et al, 2009; Wang & Yi, 2008).”
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237 · cited 2×
“Since JNK signalling plays an important role in apoptosis induction (Davis, 2000), we investigated whether this pathway was implicated in the enhanced apoptosis observed upon p38 MAPK inhibition.”
Kamata, H., Honda, S.-I., Maeda, S., Chang, L., Hirata, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2004.12.041 · Cited by 1,792
Cell transformation by the superoxide-generating oxidase Mox1
Suh, Y.-A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K., & Lambeth, J. D. (1999) · Nature · doi:10.1038/43459 · Cited by 1,480 · cited 4×
“Plasmids to express GST ‐ JNK1 and GST ‐ MKK7 proteins were kindly provided by Carme Caelles (University of Barcelona, Spain) and Roger Davis (University of Massachusetts Medical School, USA), respectively.”
InfluentialCancer cell killing via ROS: To increase or decrease, that is the question
Wang, J., & Yi, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7067 · Cited by 790 · cited 2×
“It is well established that ROS play important biological roles in cell homeostasis, but several studies have also reported that high intracellular ROS levels are usually associated with apoptosis in cancer cells (Dolado et al, 2007; Wang & Yi, 2008).”
Shen, H.-M., & Liu, Z.-G. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.056 · Cited by 629
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response
Mateescu, B., Batista, L., Cardon, M., Gruosso, T., de Feraudy, Y., Mariani, O., Nicolas, A., Meyniel, J.-P., Cottu, P., Sastre-Garau, X., et al. (2011) · Nature Medicine · doi:10.1038/nm.2512 · Cited by 502
Global proteomic assessment of the classical protein-tyrosine phosphatome and “Redoxome”
Karisch, R., Fernandez, M., Taylor, P., Virtanen, C., St-Germain, J. R., Jin, L. L., Harris, I. S., Mori, J., Mak, T. W., Senis, Y. A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.020 · Cited by 179 · cited 1×
“It is known that ROS ‐ induced oxidation of the catalytic cysteine can inhibit the activity of phosphatases (Karisch et al, 2011; Ostman et al, 2011).”
Hou, N., Torii, S., Saito, N., Hosaka, M., & Takeuchi, T. (2008) · Endocrinology · doi:10.1210/en.2007-0988 · Cited by 141
p38α Mediates Cell Survival in Response to Oxidative Stress via Induction of Antioxidant Genes
Gutiérrez-Uzquiza, Á., Arechederra, M., Bragado, P., Aguirre-Ghiso, J. A., & Porras, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323709 · Cited by 139
Cited by
Diversity and versatility of p38 kinase signalling in health and disease
Canovas, B., & Nebreda, A. R. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00322-w · Cited by 657
The p38 Pathway: From Biology to Cancer Therapy
Martínez-Limón, A., Joaquin, M., Caballero, M., Posas, F., & de Nadal, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061913 · Cited by 411
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Caspase 3/GSDME-dependent pyroptosis contributes to chemotherapy drug-induced nephrotoxicity
Shen, X., Wang, H., Weng, C., Jiang, H., & Chen, J. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03458-5 · Cited by 235
Metadata
- Authors
- Pereira, L., Igea, A., Canovas, B., Dolado, I., & Nebreda, A. R.
- Venue
- EMBO Molecular Medicine
- Published
- 2013-09-24
- Volume
- 5
- Issue
- 11
- Pages
- 1759-1774
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2136897326
- Cited by
- 138
- References
- 10
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.